DCC5141 |
Thpp-2 |
Novel phosphodiesterase 10A (PDE10A) inhibitor for treatment of schizophrenia |
|
DCC5142 |
Thpp-4 |
Phosphodiesterase 10A (PDE10A) inhibitor |
|
DCC5143 |
Thr101 |
Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9; NOX Inhibitor |
|
DCC5144 |
Thrombin-in-3g |
Novel selective thrombin inhibitor, inducing conformational allostery |
|
DCC5145 |
Thrx160209 |
Novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor |
|
DCC5146 |
Tiagabine |
Anti-epileptic and anticonvulsant agent, acting as a selective GABA reuptake inhibitor |
|
DCC5147 |
Tiancimycin |
Anthraquinone-fused enediyne antitumor agent for development of antibody-drug conjugates (ADCs) |
|
DCC5148 |
Tiemonium Iodide |
Muscarinic receptor antagonist, anticholinergic,and parasympatholytic |
|
DCC5149 |
Tigilanol Tiglate |
Natural anticancer agent fortreatment of mast cell tumor (MCT) |
|
DCC5150 |
Tillman Reagent |
Widely used oxidation-reduction indicator |
|
DCC5151 |
Tilmicosin Phosphate |
Macrolide antibiotic for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia (Pasteurella) haemolytica |
|
DCC5152 |
Tilorone Dihydrochloride |
Antiviral, antineoplastic, and anti-inflammatory agent; Orally active interferon inducer, inhibiting Ebola virus (EBOV) |
|
DCC5153 |
Tinostamustine Hydrochloride |
Novel pan-histone-deacetylase inhibitor with alkylating activity |
|
DCC5154 |
Tinyatoxin |
Neurotoxin, acting via vanilloid receptors of sensory nerves |
|
DCC5155 |
Tioxolone |
Novel hepcidin antagonist |
|
DCC5156 |
tipp-204 |
hPPAR |
|
DCC5157 |
tipp-401 |
Dual PPA |
|
DCC5158 |
tipp-703 |
hPPAR-pan agonist |
|
DCC5159 |
Tiracizine Hydrochloride |
Anti-arrhythmia agent |
|
DCC5160 |
Tl13-117 |
Novel AC220-based FLT3 degrader |
|
DCC5161 |
Tl13-149 |
Novel AC220-based FLT3 degrader |
|
DCC5162 |
Tli3-12 |
The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines |
|
DCC5163 |
Tli3-i12 |
The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines |
|
DCC5164 |
Tlk19781 |
Novel Insulin Receptor Modulator |
|
DCC5165 |
tlr4-in-c35 |
Novel Toll-Like Receptor 4 (TLR4) Inhibitor |
|
DCC5166 |
Tlr7/8-in-cmpd2 |
Novel potent and selective dual TLR7/8 inhibitor |
|
DCC5167 |
Tlr8-in-5 |
Novel toll-like receptor 8 (TLR8) inhibitor, potently and selectively reducing TLR8-mediated signaling |
|
DCC5168 |
Tls-in-5 |
The first small molecule inhibitor of translesion synthesis (TLS) that target Rev1-CT |
|
DCC5169 |
Tm2-119 |
Potent histone methyltransferase inhibitor with rapid antimalarial activity against all blood stage forms in Plasmodium falciparum |
|
DCC5170 |
Tm-233 |
Novel inhibitor of both JAK/STAT and proteasome activities, inducing cell death in myeloma cells |
|